| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ATN1 |
| Uniprot No | P54259 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1190aa |
| 氨基酸序列 | MKTRQNKDSMSMRSGRKKEAPGPREELRSRGRASPGGVSTSSSDGKAEKSRQTAKKARVEEASTPKVNKQGRSEEISESESEETNAPKKTKTEQELPRPQSPSDLDSLDGRSLNDDGSSDPRDIDQDNRSTSPSIYSPGSVENDSDSSSGLSQGPARPYHPPPLFPPSPQPPDSTPRQPEASFEPHPSVTPTGYHAPMEPPTSRMFQAPPGAPPPHPQLYPGGTGGVLSGPPMGPKGGGAASSVGGPNGGKQHPPPTTPISVSSSGASGAPPTKPPTTPVGGGNLPSAPPPANFPHVTPNLPPPPALRPLNNASASPPGLGAQPLPGHLPSPHAMGQGMGGLPPGPEKGPTLAPSPHSLPPASSSAPAPPMRFPYSSSSSSSAAASSSSSSSSSSASPFPASQALPSYPHSFPPPTSLSVSNQPPKYTQPSLPSQAVWSQGPPPPPPYGRLLANSNAHPGPFPPSTGAQSTAHPPVSTHHHHHQQQQQQQQQQQQQQQQQQQHHGNSGPPPPGAFPHPLEGGSSHHAHPYAMSPSLGSLRPYPPGPAHLPPPHSQVSYSQAGPNGPPVSSSSNSSSSTSQGSYPCSHPSPSQGPQGAPYPFPPVPTVTTSSATLSTVIATVASSPAGYKTASPPGPPPYGKRAPSPGAYKTATPPGYKPGSPPSFRTGTPPGYRGTSPPAGPGTFKPGSPTVGPGPLPPAGPSGLPSLPPPPAAPASGPPLSATQIKQEPAEEYETPESPVPPARSPSPPPKVVDVPSHASQSARFNKHLDRGFNSCARSDLYFVPLEGSKLAKKRADLVEKVRREAEQRAREEKEREREREREKEREREKERELERSVKLAQEGRAPVECPSLGPVPHRPPFEPGSAVATVPPYLGPDTPALRTLSEYARPHVMSPGNRNHPFYVPLGAVDPGLLGYNVPALYSSDPAAREREREARERDLRDRLKPGFEVKPSELEPLHGVPGPGLDPFPRHGGLALQPGPPGLHPFPFHPSLGPLERERLALAAGPALRPDMSYAERLAAERQHAERVAALGNDPLARLQMLNVTPHHHQHSHIHSHLHLHQQDAIHAASASVHPLIDPLASGSHLTRIPYPAGTLPNPLLPHPLHENEVLRHQLFAAPYRDLPASLSAPMSAAHQLQAMHAQSAELQRLALEQQQWLHAHHPLHSVPLPAQEDYYSHLKKESDKPL |
| 预测分子量 | 125,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ATN1重组蛋白的3篇文献示例(部分为假设性示例，实际文献需通过数据库验证)：
---
1. **文献名称**: "Expression and Purification of Recombinant ATN1 Protein for Neurodegenerative Disease Studies"
**作者**: Smith JL, et al.
**摘要**: 研究描述了通过大肠杆菌表达系统高效表达ATN1重组蛋白的优化方法，并利用亲和层析技术纯化蛋白。纯化后的蛋白用于体外磷酸化实验，揭示了ATN1在神经细胞凋亡中的潜在作用。
---
2. **文献名称**: "Structural Analysis of ATN1 Reveals Polyglutamine Expansion Effects"
**作者**: Tanaka K, et al.
**摘要**: 通过X射线晶体学解析了重组ATN1蛋白的3D结构，发现其多聚谷氨酰胺(PolyQ)扩展突变导致构象变化，可能破坏与转录共抑制因子的相互作用，从而引发DRPLA疾病。
---
3. **文献名称**: "ATN1 Recombinant Protein Modulates Transcriptional Repression in Cellular Models"
**作者**: Garcia R, et al.
**摘要**: 研究利用哺乳动物细胞表达体系制备ATN1重组蛋白，发现其与组蛋白脱乙酰酶(HDACs)结合并增强转录抑制活性，提示ATN1在表观遗传调控中的功能异常可能参与疾病机制。
---
**备注**：上述文献为示例性质，实际文献需通过PubMed、Google Scholar等平台以关键词“ATN1 recombinant protein”或“Atrophin-1 expression”检索。建议优先选择近5年发表的、经同行评审的研究。
**Background of ATN1 Recombinant Protein**
The **ATN1** gene encodes **Atrophin-1**, a protein implicated in transcriptional regulation and cellular signaling pathways. While its precise physiological role remains under investigation, Atrophin-1 is associated with nuclear receptor interactions, modulation of gene expression, and cytoskeletal organization. Notably, mutations in *ATN1* are linked to **dentatorubral-pallidoluysian atrophy (DRPLA)**, a rare autosomal dominant neurodegenerative disorder characterized by expanded polyglutamine (polyQ) repeats. These pathogenic repeats lead to protein aggregation, neuronal dysfunction, and selective neurodegeneration, particularly in the cerebellum and basal ganglia.
Recombinant ATN1 protein is engineered *in vitro* using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional forms of the protein for research. This tool enables studies on its native structure, post-translational modifications, and interactions with binding partners, such as transcription factors or cytoskeletal components. Researchers also utilize ATN1 recombinant protein to model DRPLA pathology, including polyQ-mediated toxicity and aggregation mechanisms.
In drug discovery, recombinant ATN1 serves as a substrate for screening therapeutic compounds aimed at inhibiting aggregation or enhancing protein clearance. Additionally, it is used to generate antibodies for diagnostic assays or to validate cellular and animal models of DRPLA. Understanding ATN1's role in health and disease through recombinant protein studies may uncover targets for mitigating neurodegeneration or regulating associated signaling pathways. However, challenges persist in replicating its full-length native conformation and post-translational modifications *in vitro*, necessitating cautious interpretation of experimental outcomes.
Overall, ATN1 recombinant protein remains a critical resource for unraveling the molecular basis of DRPLA and exploring potential therapeutic strategies.
×
